Compare Annaly Capital Management, Inc. (NLY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Annaly Capital Management, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Annaly Capital Management, Inc. trades at $22.79 (market cap $17.12B), while Vertex Pharmaceuticals Incorporated trades at $522.29 (market cap $134.06B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.8× Annaly Capital Management, Inc.'s market cap, and Annaly Capital Management, Inc. pays a 13.2% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NLY | VRTX | |
|---|---|---|
Market Cap | $17.12B | $134.06B |
Sector | Financials | Health |
52-Week High | $24.40 | $557.96 |
52-Week Low | $20.21 | $376.62 |
Dividend Yield | 13.2% | — |
Enterprise Value | — | $128.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Annaly Capital Management (NLY) trades at $22.72, down 0.39% for the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.79 exceeding the $0.751 estimate. Fundamentals show a high net income margin of 92.77% and a return on equity of 20.66%, though cash flow from operations declined to $692.91 million in 2025. Recent news includes a declared $0.75 dividend and a preferred stock redemption.
The outlook for NLY is supported by analyst consensus with a $24.33 price target and a majority buy rating, indicating potential upside. However, risks include significant investing cash outflows, high leverage with debt-to-asset ratio rising to 23.55 in 2025, and sensitivity to interest rate changes. The stock offers a high dividend yield but faces headwinds from mortgage rate volatility and tax inefficiencies for investors in taxable accounts.
Vertex Pharmaceuticals (VRTX) trades at $528.9, down 3.15% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish moving average signal but neutral oscillators, with key support at $522. Fundamentally, 2025 revenue reached $12.0B with a strong net income margin of 35%, though recent quarterly EPS results have been mixed. The company recently completed the acquisition of Crinetics Pharmaceuticals, signaling growth ambitions.
The outlook remains positive given analyst consensus favoring a Buy rating (84%) and a $548.78 price target, implying upside. Key opportunities include revenue growth from new drug launches, while risks involve competitive pressures and earnings volatility. The stock's current valuation at a P/E of 30.8 requires sustained execution to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
